Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
Afficher le documentFOREWORD
Afficher le documentACKNOWLEDGMENTS
Afficher le documentINTRODUCTION
fermer ce répertoireStandard Treatment Guidelines (STG)
ouvrir ce répertoire et afficher son contenu1. GASTROINTESTINAL CONDITIONS
ouvrir ce répertoire et afficher son contenu2. RESPIRATORY DISEASES
ouvrir ce répertoire et afficher son contenu3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
ouvrir ce répertoire et afficher son contenu4. CARDIOVASCULAR DISEASES
ouvrir ce répertoire et afficher son contenu5. MALARIA
ouvrir ce répertoire et afficher son contenu6. SKIN DISEASES
ouvrir ce répertoire et afficher son contenu7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
ouvrir ce répertoire et afficher son contenu8. DENTAL AND ORAL CONDITIONS
ouvrir ce répertoire et afficher son contenu9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
ouvrir ce répertoire et afficher son contenu10. EAR, NOSE AND THROAT CONDITIONS
ouvrir ce répertoire et afficher son contenu11. EYE CONDITIONS
fermer ce répertoire12. TUBERCULOSIS AND LEPROSY
ouvrir ce répertoire et afficher son contenu12.1 Tuberculosis
fermer ce répertoire12.2 Leprosy
ouvrir ce répertoire et afficher son contenu12.2.1 General Information about Leprosy
fermer ce répertoire12.2.2 Classification of Leprosy
Afficher le document12.2.2.1 Tuberculoid Leprosy
Afficher le document12.2.2.2 Borderline Leprosy
Afficher le document12.2.2.3 Borderline Tuberculoid (BT) Leprosy
Afficher le document12.2.2.4 Borderline Lepromatous (BL) Leprosy
Afficher le document12.2.2.5 Lepromatous (LL) leprosy
ouvrir ce répertoire et afficher son contenu12.3 Treatment of Leprosy
Afficher le document12.4 Prevention of Disabilities and rehabilitation
ouvrir ce répertoire et afficher son contenu12.5 Signs and Treatment of Severe Reversal Reaction (RR)
Afficher le document12.6 Responsibilities
Afficher le document12.7 How to Look After Ulcers
Afficher le document12.8 Surveillance of Patients After Release from MDT
Afficher le document12.9 Referral Criteria of Leprosy Patients
ouvrir ce répertoire et afficher son contenu13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
ouvrir ce répertoire et afficher son contenu14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
ouvrir ce répertoire et afficher son contenu15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu16. OTHER DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu17. VIRAL INFECTIONS
ouvrir ce répertoire et afficher son contenu18. ALLERGIC REACTIONS
ouvrir ce répertoire et afficher son contenu19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
ouvrir ce répertoire et afficher son contenu20. MALIGNANT DISEASE CONDITIONS
ouvrir ce répertoire et afficher son contenu21. INJURIES AND TRAUMA
Afficher le document22. FOREIGN BODIES
Afficher le document23. PAIN
Afficher le document24. POISONING
Afficher le document25. NORMAL LABORATORY VALUES
ouvrir ce répertoire et afficher son contenuNATIONAL ESSENTIAL DRUG LIST
Afficher le documentABBREVIATIONS AND SYMBOLS
 
12.2.2 Classification of Leprosy

The diagnosis and the classification of leprosy is made on clinical grounds. Skin smear result confirm the clinical classification. It is important to remember that all types of leprosy are caused by only one kind of bacillus: Mycobacterium leprae. In every leprosy patient these bacilli are present somewhere in the body even if skin smears are negative. Leprosy is classified into two main groups depending on the number of bacilli present in the body. Patients with many bacilli belong to the multi bacillary group, while those with few bacilli belong to the paucibacillary group. These groups are subdivided into four main types which are:

Table: Classification of Leprosy (Ridley-Jopling System)

FEW BACILLI

MANY BACILLI

Tuberculoid

Borderline Tuberculoid

Borderline Borderline

Borderline Lepromatous

Lepromatous

T.T

B.T

B.B

BL

L.L

Patients with tuberculoid leprosy are loss infectious (due to few bacilli) but are more likely to suffer paralysis of peripheral nerves.

Treatment guidelines

These are given according to the National TB and Leprosy Programme:

1. Dapsone monotherapy

Adults:

100 mg every 24 hours for 5 years or more

Children:

 

40 kg or more:

100 mg every 24 hours for 5 years or more.

20 - 40 kg:

50 mg daily for 5 years or more.

under 20 kg:

25 mg daily for 5 years or more.

2. Multiple Drug Therapy (MDT)

Recommended to prevent or treat drug resistance and to cure patients in a shorter period of time. For multi-bacillary (BL-L) patients give Rifampicin and Isoprodian (Isoniazid 175 mg, Prothyonamide 175 mg, Dapsone 50 mg) daily for 1 month (4 weeks) under supervision followed by Isoprodian daily for 23 months plus a single dose of Rifampicin under supervision every 4 weeks (1 R Isop /23 Isop(R)} or Isoprodian daily for 24 months plus a single dose of Rifampicin under supervision every 4 weeks (24 Isop (R)}.

For paucibacillary (BT-T) patients, give Isoprodian daily for 6 months plus a single dose of Rifampicin under supervision every 4 weeks (6 Isop (R)}.

Table: Dosage adjustment to patient's body weight

Body Weight (kgs)

Isoprodian tablets

Rifampicin

20

1

2

30

1

2

40

1

3

50

1

3

60

2

4

70

2

4

80

2

4

90

3

4

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires
Abréviations
Anglais  |  Français